Results 1 to 10 of about 84,266 (263)

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting [PDF]

Frontiers in Immunology, 2023
Cancerous B cells are almost indistinguishable from their non-malignant counterparts regarding their surface antigen expression. Accordingly, the challenge to be faced consists in elimination of the malignant B cell population while maintaining a ...
Katrin Schoenfeld, Julia Harwardt, Jan Habermann, Adrian Elter, Harald Kolmar, Harald Kolmar   +5 more
doaj   +2 more sources

Applications of Pharmacometrics in Antibody–Drug Conjugate Development [PDF]

Pharmaceutics
Antibody–drug conjugates (ADCs), which integrate a cytotoxic drug known as the payload into a tumor-targeting monoclonal antibody via a linker, have emerged as promising candidates for cancer therapy and are a new avenue for targeted cancer therapy.
Xiaoliang Cheng, Shuangmin Ji, Yonghyun Lee, Haiyan Dong   +3 more
doaj   +2 more sources

CD74-Targeted Cathepsin-Inhibitor Antibody–Drug Conjugate Triggers Apoptosis in DLBCL [PDF]

Cells
Transcriptomic analyses of public datasets (TCGA and GTEx) revealed that both CD74 and Cathepsin L (CTSL) are significantly overexpressed in diffuse large B-cell lymphoma (DLBCL) compared to normal tissues, and that their expression levels are highly ...
Ihab Abd-Elrahman, Noha Khairi, Reut Sinai-Turyansky, Ivan Zlotber, Riki Perlman, Emmanuelle Merquiol, Galia Blum, Dina Ben Yehuda   +7 more
doaj   +2 more sources

Novel Immune Checkpoint Inhibitor and Antibody–Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer [PDF]

Current Oncology
Immune checkpoint inhibitors and antibody drug conjugate combinations have revolutionized the management of patients with advanced and metastatic urothelial carcinoma, offering unprecedented survival outcomes. These treatments are now moving into earlier
Joseph Vento, Tian Zhang, Yair Lotan, Solomon Woldu, Qian Qin   +4 more
doaj   +2 more sources

HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer [PDF]

Cancer Medicine
Background HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other ...
Seohyuk Lee, Adriana M. Kahn, Mariya Rozenblit, Mridula A. George, Cristina Naranjo Ortiz, Maryam B. Lustberg   +5 more
doaj   +2 more sources

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy

Pharmaceuticals, 2022
Although there have been extensive research and progress on the discovery of anticancer drug over the years, the application of these drugs as stand-alone therapy has been limited by their off-target toxicities, poor pharmacokinetic properties, and low ...
Audrey Nathania Johan, Yi Li
doaj   +1 more source

Antibody–Drug Conjugate to Treat Meningiomas

Pharmaceuticals, 2021
Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control ...
Kai Chen, Yingnan Si, Jianfa Ou, Jia-Shiung Guan, Seulhee Kim, Patrick Ernst, Ya Zhang, Lufang Zhou, Xiaosi Han, Xiaoguang (Margaret) Liu   +9 more
doaj   +1 more source

Specific ablation of PDGFRβ-overexpressing pericytes with antibody-drug conjugate potently inhibits pathologic ocular neovascularization in mouse models

Communications Medicine, 2021
Lee et al. use an antibody-drug conjugate to treat pathologic ocular neovascularization in mouse models. The antibody-drug conjugate targets PDGFRβ-expressing pericytes, with similar therapeutic effects to an anti-VEGF agent and with limited unwanted ...
Seok Jae Lee, Soohyun Kim, Dong Hyun Jo, Chang Sik Cho, Su Ree Kim, Dongmin Kang, Jisu Chae, Duck Kyun Yoo, Suji Ha, Junho Chung, Jeong Hun Kim   +10 more
doaj   +1 more source

Anti-VEGFR2 F(ab′)2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy

Nature Communications, 2023
Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab′)
Di Liu, Yanling Song, Hui Chen, Yuchan You, Luwen Zhu, Jucong Zhang, Xinyi Xu, Jiahao Hu, Xiajie Huang, Xiaochuan Wu, Xiaoling Xu, Saiping Jiang, Yongzhong Du   +12 more
doaj   +1 more source

Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat [PDF]

Journal of Immunotherapy and Precision Oncology
Kathy L. Chan, Saadia A. Faiz, Ajay Sheshadri   +2 more
doaj   +2 more sources